Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann & Co Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and we ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP & Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Ahu Demir - Ladenburg Thalmann & Co. Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharma ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2021 Results Conference Call March 28, 2022 4:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Ahu Demir - Ladenburg Jonathan Aschoff - ROTH Capital Kumar Raja - Brookline Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2021 Results Conference Call an ...

Translating cancer biology into medicines Corporate Presentation February 2022 Disclaimer This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forwardlooking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candida ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Kumar Raja - Brookline Capital Suzanne Rismiller - Oppenheimer Operator Good afternoon and welcome to the Cyclacel Pharmaceu ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kumar Raja - Brooklyn Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals’ Second Quarter 2021 Results Conference Call and Webcast. At this time, all participants are in a listen-only mo ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2021 Earnings Conference Call May 12, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kevin DeGeeter - Oppenheimer Wangzhi Li - Ladenburg Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2021 Results Conference Call and Webcast. At this time, all participants are in a liste ...

Translating cancer biology into medicines March 15, 2021 33rd Annual Roth Conference Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. ("Cyclacel"). By their nature, forward-looking statements and forecasts involve risks and uncertainties ...

Translating cancer biology into medicines February 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend o ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum – Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff – Roth Capital Partners Kumar Raja – Brookline Capital Wangzhi Li – Ladenburg Operator Good afternoon, and w ...